Skip to Main content Skip to Navigation
Journal articles

Quality of life predicts outcome of deep brain stimulation in early Parkinson disease

W.M. Michael Schuepbach 1, 2, 3 Lisa Tonder 4 Alfons Schnitzler 5 Paul Krack 6 Joern Rau 7 Andreas Hartmann 8 Thomas Hälbig 9 Fanny Pineau 10 Andrea Falk 11 Laura Paschen 12 Stephen Paschen 13 Jens Volkmann 14 Haidar Dafsari 15, 16 Michael Barbe 15 Gereon Fink 17 Andrea Kühn 18, 19 Andreas Kupsch 20 Gerd-H. Schneider 21 Eric Seigneuret 22 Valérie Fraix 23 Andrea Kistner 24 P. Patrick Chaynes 25 Fabienne Ory-Magne 26 Christine Brefel-Courbon 26 Jan Vesper 27 Lars Wojtecki 5 Stéphane Derrey 28, 29, 30, 31 David Maltête 32 Philippe Damier 33 Pascal Derkinderen 34 Friederike Sixel-Döring 35, 36 Claudia Trenkwalder 37 Alireza Gharabaghi 38 Tobias Wächter 39 Daniel Weiss 40 Marcus O. Pinsker 14 Jean-Marie Regis 41 Tatiana Witjas 42 Stéphane Thobois 43 Patrick Mertens 44 Karina Knudsen 45 Carmen Schade-Brittinger 46 Jean-Luc Houeto 47, 48 Yves Agid 49 Marie Vidailhet 50 Lars Timmermann 5 Günther Deuschl 14 
Abstract : Objective To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications. Methods We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson’s Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS) (UPDRS-III“off”and “on” medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI. Results PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group. Conclusion Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.
Complete list of metadata
Contributor : Alexis GOICHON Connect in order to contact the contributor
Submitted on : Wednesday, November 20, 2019 - 5:25:40 PM
Last modification on : Friday, August 5, 2022 - 2:33:47 PM

Links full text



W.M. Michael Schuepbach, Lisa Tonder, Alfons Schnitzler, Paul Krack, Joern Rau, et al.. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, American Academy of Neurology, 2019, 92 (10), pp.e1109-e1120. ⟨10.1212/WNL.0000000000007037⟩. ⟨hal-02373051⟩